The cell free tumor deoxyribonucleic acid (dna) detection market size has grown rapidly in recent years. It will grow from $2.58 billion in 2025 to $3.02 billion in 2026 at a compound annual growth rate (CAGR) of 17.2%. The growth in the historic period can be attributed to growing cancer prevalence, advancements in molecular diagnostics, rising demand for non-invasive testing, adoption of PCR and NGS techniques, increasing clinical research studies.
The cell free tumor deoxyribonucleic acid (dna) detection market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2030 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to expansion of precision medicine, technological innovations in ctDNA analysis, integration with AI-based diagnostics, rising healthcare investments in emerging economies, growth in early cancer detection programs. Major trends in the forecast period include liquid biopsy adoption, integration with genomic data platforms, real-time tumor monitoring, non-invasive cancer diagnostics, advanced ctdna detection technologies.
The growing demand for personalized medicine is expected to contribute to the expansion of the cell free tumor deoxyribonucleic acid detection market in the coming years. Personalized medicine is a healthcare approach that customizes treatment and prevention strategies according to an individual's specific genetic profile, lifestyle, and environmental factors. This approach is gaining momentum due to advancements in genomics, which make it possible to identify genetic variations with precision and create tailored treatment plans. Cell free tumor deoxyribonucleic acid detection supports personalized medicine by offering non-invasive, real-time information about the genetic characteristics of a patient's tumor. It allows healthcare providers to customize treatment based on individual mutation profiles, track therapeutic responses, and identify disease recurrence at an early stage, leading to improved patient outcomes and greater accuracy in cancer care. For example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the United States, reported that the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, a considerable rise from the 12 approved in 2022. As a result, the increasing demand for personalized medicine is contributing to the growth of the cell free tumor deoxyribonucleic acid detection market.
Leading companies in the cell free tumor deoxyribonucleic acid detection market are focusing on creating advanced products such as library preparation kits that improve the accuracy, sensitivity, and speed of cancer testing. Library preparation kits are reagent products used to prepare DNA or RNA samples for sequencing by breaking them into smaller fragments, tagging them, and amplifying them for more accurate analysis. For instance, in February 2024, Twist Bioscience Corporation, a biotechnology company based in the United States, introduced the cfDNA Library Preparation Kit to improve the sensitivity and accuracy of liquid biopsy applications. This kit allows for efficient generation of cell free DNA libraries suitable for next-generation sequencing on Illumina platforms, helping overcome issues associated with low-input and degraded DNA samples. The goal of this innovation is to enhance the reliability and effectiveness of liquid biopsy testing, supporting earlier cancer detection and better monitoring of treatment responses.
In April 2023, Quest Diagnostics Incorporated, a US-based provider of diagnostic testing, information, and services, completed the acquisition of Haystack Oncology Inc. for an undisclosed sum. Through this acquisition, Quest Diagnostics intends to expand its oncology portfolio by incorporating Haystack’s advanced liquid biopsy technology, aimed at enhancing the precision of cancer detection and supporting personalized treatment approaches. Haystack Oncology, Inc. is a US-based precision oncology firm that focuses on cell-free tumor DNA (cfDNA) detection and liquid biopsy diagnostics.
Major companies operating in the cell free tumor deoxyribonucleic acid (dna) detection market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Illumina Inc., Sysmex Inostics Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Guardant Health Inc., Invitae Corporation, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Biodesix Inc, Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems SpA, Exosome Diagnostics Inc., Lucence Health Inc.
North America was the largest region in the cell free tumor deoxyribonucleic acid (DNA) detection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free tumor deoxyribonucleic acid (dna) detection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell free tumor deoxyribonucleic acid (dna) detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the cell free tumor DNA detection market by raising import costs of reagents, kits, and sequencing instruments, impacting hospitals and diagnostic laboratories. Regions like north america and asia-pacific that rely on imported instruments are most affected. While tariffs increase operational costs, they encourage local production of detection kits and foster innovation in cost-effective, high-precision ctDNA technologies.
The cell free tumor deoxyribonucleic acid (dna) detection market research report is one of a series of new reports that provides cell free tumor deoxyribonucleic acid (dna) detection market statistics, including cell free tumor deoxyribonucleic acid (dna) detection industry global market size, regional shares, competitors with a cell free tumor deoxyribonucleic acid (dna) detection market share, detailed cell free tumor deoxyribonucleic acid (dna) detection market segments, market trends and opportunities, and any further data you may need to thrive in the cell free tumor deoxyribonucleic acid (dna) detection industry. This cell free tumor deoxyribonucleic acid (dna) detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell-free tumor deoxyribonucleic acid (DNA) detection is a non-invasive diagnostic method that identifies and analyzes small DNA fragments released into the bloodstream by cancer cells. It provides real-time information on genetic mutations, tumor burden, and disease progression without the need for tissue biopsies. The main purpose is to enable early cancer detection, monitor treatment response, and track minimal residual disease or relapse.
The primary technologies used in cell-free tumor deoxyribonucleic acid (DNA) detection are polymerase chain reaction (PCR), next-generation sequencing (NGS), and digital polymerase chain reaction (dPCR). Polymerase chain reaction (PCR) is a technique that rapidly amplifies specific DNA segments, allowing detection of even minute amounts of tumor DNA. Sample sources include plasma, serum, and urine. Applications cover oncology, non-invasive prenatal testing, transplantation, and other areas. Key end-users include hospitals, diagnostic laboratories, academic and research institutions, and related organizations.
The cell free tumor deoxyribonucleic acid (DNA) detection market consists of revenues earned by entities by providing services such as early cancer screening, liquid biopsy testing, genomic profiling, treatment response monitoring, and personalized therapy selection. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell free tumor deoxyribonucleic acid (DNA) detection market also includes sales of liquid biopsy kits, next-generation sequencing (NGS) platforms, target enrichment kits, bioinformatics and data analysis software, microfluidics-based detection platforms, and automated liquid handling systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cell free tumor deoxyribonucleic acid (dna) detection market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2030 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to expansion of precision medicine, technological innovations in ctDNA analysis, integration with AI-based diagnostics, rising healthcare investments in emerging economies, growth in early cancer detection programs. Major trends in the forecast period include liquid biopsy adoption, integration with genomic data platforms, real-time tumor monitoring, non-invasive cancer diagnostics, advanced ctdna detection technologies.
The growing demand for personalized medicine is expected to contribute to the expansion of the cell free tumor deoxyribonucleic acid detection market in the coming years. Personalized medicine is a healthcare approach that customizes treatment and prevention strategies according to an individual's specific genetic profile, lifestyle, and environmental factors. This approach is gaining momentum due to advancements in genomics, which make it possible to identify genetic variations with precision and create tailored treatment plans. Cell free tumor deoxyribonucleic acid detection supports personalized medicine by offering non-invasive, real-time information about the genetic characteristics of a patient's tumor. It allows healthcare providers to customize treatment based on individual mutation profiles, track therapeutic responses, and identify disease recurrence at an early stage, leading to improved patient outcomes and greater accuracy in cancer care. For example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the United States, reported that the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, a considerable rise from the 12 approved in 2022. As a result, the increasing demand for personalized medicine is contributing to the growth of the cell free tumor deoxyribonucleic acid detection market.
Leading companies in the cell free tumor deoxyribonucleic acid detection market are focusing on creating advanced products such as library preparation kits that improve the accuracy, sensitivity, and speed of cancer testing. Library preparation kits are reagent products used to prepare DNA or RNA samples for sequencing by breaking them into smaller fragments, tagging them, and amplifying them for more accurate analysis. For instance, in February 2024, Twist Bioscience Corporation, a biotechnology company based in the United States, introduced the cfDNA Library Preparation Kit to improve the sensitivity and accuracy of liquid biopsy applications. This kit allows for efficient generation of cell free DNA libraries suitable for next-generation sequencing on Illumina platforms, helping overcome issues associated with low-input and degraded DNA samples. The goal of this innovation is to enhance the reliability and effectiveness of liquid biopsy testing, supporting earlier cancer detection and better monitoring of treatment responses.
In April 2023, Quest Diagnostics Incorporated, a US-based provider of diagnostic testing, information, and services, completed the acquisition of Haystack Oncology Inc. for an undisclosed sum. Through this acquisition, Quest Diagnostics intends to expand its oncology portfolio by incorporating Haystack’s advanced liquid biopsy technology, aimed at enhancing the precision of cancer detection and supporting personalized treatment approaches. Haystack Oncology, Inc. is a US-based precision oncology firm that focuses on cell-free tumor DNA (cfDNA) detection and liquid biopsy diagnostics.
Major companies operating in the cell free tumor deoxyribonucleic acid (dna) detection market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Illumina Inc., Sysmex Inostics Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Guardant Health Inc., Invitae Corporation, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, Freenome Holdings Inc., Grail Inc., Biodesix Inc, Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems SpA, Exosome Diagnostics Inc., Lucence Health Inc.
North America was the largest region in the cell free tumor deoxyribonucleic acid (DNA) detection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free tumor deoxyribonucleic acid (dna) detection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell free tumor deoxyribonucleic acid (dna) detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the cell free tumor DNA detection market by raising import costs of reagents, kits, and sequencing instruments, impacting hospitals and diagnostic laboratories. Regions like north america and asia-pacific that rely on imported instruments are most affected. While tariffs increase operational costs, they encourage local production of detection kits and foster innovation in cost-effective, high-precision ctDNA technologies.
The cell free tumor deoxyribonucleic acid (dna) detection market research report is one of a series of new reports that provides cell free tumor deoxyribonucleic acid (dna) detection market statistics, including cell free tumor deoxyribonucleic acid (dna) detection industry global market size, regional shares, competitors with a cell free tumor deoxyribonucleic acid (dna) detection market share, detailed cell free tumor deoxyribonucleic acid (dna) detection market segments, market trends and opportunities, and any further data you may need to thrive in the cell free tumor deoxyribonucleic acid (dna) detection industry. This cell free tumor deoxyribonucleic acid (dna) detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cell-free tumor deoxyribonucleic acid (DNA) detection is a non-invasive diagnostic method that identifies and analyzes small DNA fragments released into the bloodstream by cancer cells. It provides real-time information on genetic mutations, tumor burden, and disease progression without the need for tissue biopsies. The main purpose is to enable early cancer detection, monitor treatment response, and track minimal residual disease or relapse.
The primary technologies used in cell-free tumor deoxyribonucleic acid (DNA) detection are polymerase chain reaction (PCR), next-generation sequencing (NGS), and digital polymerase chain reaction (dPCR). Polymerase chain reaction (PCR) is a technique that rapidly amplifies specific DNA segments, allowing detection of even minute amounts of tumor DNA. Sample sources include plasma, serum, and urine. Applications cover oncology, non-invasive prenatal testing, transplantation, and other areas. Key end-users include hospitals, diagnostic laboratories, academic and research institutions, and related organizations.
The cell free tumor deoxyribonucleic acid (DNA) detection market consists of revenues earned by entities by providing services such as early cancer screening, liquid biopsy testing, genomic profiling, treatment response monitoring, and personalized therapy selection. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell free tumor deoxyribonucleic acid (DNA) detection market also includes sales of liquid biopsy kits, next-generation sequencing (NGS) platforms, target enrichment kits, bioinformatics and data analysis software, microfluidics-based detection platforms, and automated liquid handling systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Characteristics
3. Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Supply Chain Analysis
4. Global Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Trends and Strategies
5. Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Analysis of End Use Industries
7. Global Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Total Addressable Market (TAM) Analysis for the Market
9. Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Segmentation
10. Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Regional and Country Analysis
11. Asia-Pacific Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
12. China Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
13. India Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
14. Japan Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
15. Australia Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
16. Indonesia Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
17. South Korea Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
18. Taiwan Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
19. South East Asia Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
20. Western Europe Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
21. UK Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
22. Germany Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
23. France Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
24. Italy Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
25. Spain Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
26. Eastern Europe Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
27. Russia Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
28. North America Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
29. USA Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
30. Canada Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
31. South America Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
32. Brazil Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
33. Middle East Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
34. Africa Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
36. Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Competitive Landscape and Company Profiles
37. Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Other Major and Innovative Companies
40. Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cell free tumor deoxyribonucleic acid (dna) detection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cell free tumor deoxyribonucleic acid (dna) detection? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell free tumor deoxyribonucleic acid (dna) detection market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Technology: Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Digital Polymerase Chain Reaction (dPCR)2) By Source: Plasma; Serum; Urine
3) By Application: Oncology; Non-Invasive Prenatal Testing; Transplantation; Other Applications
4) By End-User: Hospitals; Diagnostic Laboratories; Academic And Research Institutes; Other End-Users
Subsegments:
1) By Polymerase Chain Reaction (PCR): Real-Time Polymerase Chain Reaction (qPCR); Multiplex Polymerase Chain Reaction (PCR); Allele-Specific Polymerase Chain Reaction (PCR); High-Resolution Melting (HRM) Analysis; Beaming Polymerase Chain Reaction (PCR)2) By Next-Generation Sequencing (NGS): Whole Genome Sequencing (WGS); Whole Exome Sequencing (WES); Targeted Gene Panels; Ribonucleic Acid Sequencing (RNA-seq); Methylation Sequencing
3) By Digital Polymerase Chain Reaction (dPCR): Droplet Digital Polymerase Chain Reaction (ddPCR); Chip-Based Digital Polymerase Chain Reaction (PCR); Nanofluidic Digital Polymerase Chain Reaction (PCR)
Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Labcorp Holdings Inc.; Illumina Inc.; Sysmex Inostics Inc.; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Natera Inc.; Guardant Health Inc.; Invitae Corporation; Foundation Medicine Inc; Adaptive Biotechnologies Corporation; Freenome Holdings Inc.; Grail Inc.; Biodesix Inc; Personal Genome Diagnostics Inc.; Agena Bioscience Inc.; Menarini Silicon Biosystems SpA; Exosome Diagnostics Inc.; Lucence Health Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection market report include:- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Labcorp Holdings Inc.
- Illumina Inc.
- Sysmex Inostics Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN N.V.
- Natera Inc.
- Guardant Health Inc.
- Invitae Corporation
- Foundation Medicine Inc
- Adaptive Biotechnologies Corporation
- Freenome Holdings Inc.
- Grail Inc.
- Biodesix Inc
- Personal Genome Diagnostics Inc.
- Agena Bioscience Inc.
- Menarini Silicon Biosystems SpA
- Exosome Diagnostics Inc.
- Lucence Health Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.02 Billion |
| Forecasted Market Value ( USD | $ 5.64 Billion |
| Compound Annual Growth Rate | 16.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 20 |
